Biosynthesis of rapamycin and its regulation: past achievements and recent progress

Rapamycin and its analogs are clinically important macrolide compounds produced by Streptomyces hygroscopicus. They exhibit antifungal, immunosuppressive, antitumor, neuroprotective and antiaging activities. The core macrolactone ring of rapamycin is biosynthesized by hybrid type I modular polyketide synthase (PKS)/nonribosomal peptide synthetase systems primed with 4,5-dihydrocyclohex-1-ene-carboxylic acid. The linear polyketide chain is condensed with pipecolate by peptide synthetase, followed by cyclization to form the macrolide ring and modified by a series of post-PKS tailoring steps. The aim of this review was to outline past and recent advances in the biosynthesis and regulation of rapamycin, with an emphasis on the distinguished contributions of Professor Demain to the study of rapamycin. In addition, this article describes the biological activities as well as mechanism of action of rapamycin and its derivatives. Recent attempts to improve the productivity of rapamycin and generate diverse rapamycin analogs through mutasynthesis and mutagenesis are also introduced, along with some future perspectives.

[1]  D. Jelinek,et al.  Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycin. , 1994, Cellular immunology.

[2]  A. Fang,et al.  Enhancement of the antifungal activity of rapamycin by the coproduced elaiophylin and nigericin. , 2000, The Journal of antibiotics.

[3]  A. Demain,et al.  The immediate precursor of the nitrogen-containing ring of rapamycin is free pipecolic acid , 1993 .

[4]  T. Watts,et al.  Identification of an isozymic form of acetyl-CoA carboxylase. , 1990, The Journal of biological chemistry.

[5]  A. Demain,et al.  Effect of amino acids on rapamycin biosynthesis by Streptomyces hygroscopicus , 1995, Applied Microbiology and Biotechnology.

[6]  M. Gregory,et al.  Isolation and characterization of pre-rapamycin, the first macrocyclic intermediate in the biosynthesis of the immunosuppressant rapamycin by S. hygroscopicus. , 2004, Angewandte Chemie.

[7]  F. Dumont,et al.  Mechanism of action of the immunosuppressant rapamycin. , 1995, Life sciences.

[8]  M. Marahiel,et al.  Gramicidin S biosynthesis operon containing the structural genes grsA and grsB has an open reading frame encoding a protein homologous to fatty acid thioesterases , 1989, Journal of bacteriology.

[9]  S. Sehgal,et al.  Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. , 1975, The Journal of antibiotics.

[10]  Young Ji Yoo,et al.  Enhanced FK506 production in Streptomyces clavuligerus CKD1119 by engineering the supply of methylmalonyl-CoA precursor , 2009, Journal of Industrial Microbiology & Biotechnology.

[11]  M. Marahiel,et al.  The tyrocidine biosynthesis operon of Bacillus brevis: complete nucleotide sequence and biochemical characterization of functional internal adenylation domains , 1997, Journal of bacteriology.

[12]  S. Snyder,et al.  Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A , 1997, Nature Medicine.

[13]  E. Gelfand,et al.  Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle , 1993, Journal of cellular physiology.

[14]  A. Demain.  Pickles, pectin, and penicillin. , 2004, Annual review of microbiology.

[15]  A. Demain,et al.  Incorporation of acetate, propionate, and methionine into rapamycin by Streptomyces hygroscopicus. , 1991, Journal of natural products.

[16]  P. Leadlay,et al.  Organization of the biosynthetic gene cluster for rapamycin in Streptomyces hygroscopicus: analysis of the enzymatic domains in the modular polyketide synthase. , 1996, Gene.

[17]  Michael G Thomas,et al.  Biosynthesis of Polyketide Synthase Extender Units , 2009 .

[18]  R. Abraham,et al.  Mammalian target of rapamycin as a therapeutic target in oncology. , 2008, Expert opinion on therapeutic targets.

[19]  D. Sabatini,et al.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. , 2006, Molecular cell.

[20]  A. Demain,et al.  An unexpected inhibitory effect of rapamycin against germination of spores of Bacillus brevis strain Nagano. , 2002, The Journal of antibiotics.

[21]  E. Ongini,et al.  Rapamycin, but not FK506 and GPI-1046, increases neurite outgrowth in PC12 cells by inhibiting cell cycle progression , 2000, Neuropharmacology.

[22]  K. Chater,et al.  Accumulation of bldA-specified tRNA is temporally regulated in Streptomyces coelicolor A3(2) , 1993, Journal of bacteriology.

[23]  S. Sehgal,et al.  Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. , 1975, The Journal of antibiotics.

[24]  J. Caballero,et al.  The act cluster contains regulatory and antibiotic export genes, direct targets for translational control by the bldA tRNA gene of streptomyces , 1991, Cell.

[25]  Zhinan Xu,et al.  Generation of high-yield rapamycin-producing strains through protoplasts-related techniques , 2009, Applied Microbiology and Biotechnology.

[26]  E. Graziani,et al.  Novel sulfur-containing rapamycin analogs prepared by precursor-directed biosynthesis. , 2003, Organic letters.

[27]  A. Demain,et al.  Mutagenesis of the rapamycin producer Streptomyces hygroscopicus FC904. , 2001, The Journal of antibiotics.

[28]  A. D. Buss,et al.  Engineering a polyketide with a longer chain by insertion of an extra module into the erythromycin-producing polyketide synthase. , 2001, Chemistry & biology.

[29]  P. Huie,et al.  Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels. , 1993, Transplantation.

[30]  F. Bernhard,et al.  Initiation of surfactin biosynthesis and the role of the SrfD-thioesterase protein. , 2004, Biochemistry.

[31]  A. Demain,et al.  Exogenous shikimic acid stimulates rapamycin biosynthesis inStreptomyces hygroscopicus , 2008, Folia Microbiologica.

[32]  S. Thiru,et al.  RAPAMYCIN FOR IMMUNOSUPPRESSION IN ORGAN ALLOGRAFTING , 1989, The Lancet.

[33]  M. Gregory,et al.  Roles of rapH and rapG in Positive Regulation of Rapamycin Biosynthesis in Streptomyces hygroscopicus , 2007, Journal of bacteriology.

[34]  Nahum Sonenberg,et al.  Dissecting the role of mTOR: lessons from mTOR inhibitors. , 2010, Biochimica et biophysica acta.

[35]  A. Demain,et al.  Secondary metabolism in simulated microgravity. , 2001, Chemical record.

[36]  James Staunton,et al.  New Rapamycin Derivatives by Precursor‐Directed Biosynthesis , 2004, Chembiochem : a European journal of chemical biology.

[37]  R. Abraham,et al.  Mammalian target of rapamycin as a therapeutic target in oncology , 2008 .

[38]  C. Hutchinson,et al.  Sequence and transcriptional analysis of the Streptomyces glaucescens tcmAR tetracenomycin C resistance and repressor gene loci , 1992, Journal of bacteriology.

[39]  G. Kroemer,et al.  Current development of mTOR inhibitors as anticancer agents , 2006, Nature Reviews Drug Discovery.

[40]  A. Demain,et al.  The cyclohexane moiety of rapamycin is derived from shikimic acid inStreptomyces hygroscopicus , 1993, Journal of Industrial Microbiology.

[41]  N. Kelleher,et al.  Biosynthesis of pipecolic acid by RapL, a lysine cyclodeaminase encoded in the rapamycin gene cluster. , 2006, Journal of the American Chemical Society.

[42]  C. Watson.  Sirolimus (rapamycin) in clinical transplantation , 2001 .

[43]  J. Heitman,et al.  FK 506-binding protein proline rotamase is a target for the immunosuppressive agent FK 506 in Saccharomyces cerevisiae. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[44]  E. Graziani,et al.  Production of Novel Rapamycin Analogs by Precursor-Directed Biosynthesis , 2005, Applied and Environmental Microbiology.

[45]  J. Sredy,et al.  Rapamycin prevents the onset of insulin‐dependent diabetes mellitus (IDDM) in NOD mice , 1992, Clinical and experimental immunology.

[46]  R F Standaert,et al.  Atomic structure of FKBP-FK506, an immunophilin-immunosuppressant complex , 1991, Science.

[47]  A. Demain,et al.  Effect of nitrogen source on biosynthesis of rapamycin by Streptomyces hygroscopicus , 1997, Journal of Industrial Microbiology and Biotechnology.

[48]  K. O. Elliston,et al.  Structural organization of a multifunctional polyketide synthase involved in the biosynthesis of the macrolide immunosuppressant FK506. , 1997, European journal of biochemistry.

[49]  R. Morris,et al.  Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease , 1991, The Lancet.

[50]  A. Whitworth,et al.  Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss , 2009, Nature Neuroscience.

[51]  Robert Hermann,et al.  Methods for Intense Aeration, Growth, Storage, and Replication of Bacterial Strains in Microtiter Plates , 2000, Applied and Environmental Microbiology.

[52]  Antifungal Activities of Rapamycin and Its Derivatives, Prolylrapamycin, 32-Desmethylrapamycin, and 32-Desmethoxyrapamycin. , 1998 .

[53]  Christine J. Martin,et al.  Rapamycin biosynthesis: Elucidation of gene product function. , 2006, Organic & biomolecular chemistry.

[54]  P. Leadlay,et al.  Mutational Biosynthesis of Novel Rapamycins by a Strain of Streptomyces hygroscopicus NRRL 5491 Disrupted inrapL, Encoding a Putative Lysine Cyclodeaminase , 1998, Journal of bacteriology.

[55]  T. Kieser.  Practical streptomyces genetics , 2000 .

[56]  P. Leadlay,et al.  The biosynthetic gene cluster for the polyketide immunosuppressant rapamycin. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[57]  A. Demain,et al.  Carbon source nutrition of rapamycin biosynthesis inStreptomyces hygroscopicus , 1995, Journal of Industrial Microbiology.

[58]  A. Demain,et al.  Genetic improvement of processes yielding microbial products. , 2006, FEMS microbiology reviews.

[59]  P. Leadlay,et al.  The pipecolate-incorporating enzyme for the biosynthesis of the immunosuppressant rapamycin--nucleotide sequence analysis, disruption and heterologous expression of rapP from Streptomyces hygroscopicus. , 1997, European journal of biochemistry.

[60]  J. Douros,et al.  New antitumor substances of natural origin. , 1981, Cancer treatment reviews.

[61]  S. Sehgal,et al.  Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.:II. FERMENTATION, ISOLATION AND CHARACTERIZATION , 1975 .

[62]  Barry D Kahan,et al.  Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study , 2000, The Lancet.

[63]  A. Demain,et al.  Methionine Interference in Rapamycin Production Involves Repression of Demethylrapamycin Methyltransferase andS-Adenosylmethionine Synthetase , 2000, Antimicrobial Agents and Chemotherapy.

[64]  D. Bergsma,et al.  Rapamycin sensitivity in Saccharomyces cerevisiae is mediated by a peptidyl-prolyl cis-trans isomerase related to human FK506-binding protein. , 1991, Molecular and cellular biology.

[65]  P. Leadlay,et al.  Organisation of the biosynthetic gene cluster for rapamycin in Streptomyces hygroscopicus: analysis of genes flanking the polyketide synthase. , 1996, Gene.

[66]  E. Graziani,et al.  Recent advances in the chemistry, biosynthesis and pharmacology of rapamycin analogs. , 2009, Natural product reports.

[67]  M. Farrer.  Genetics of Parkinson disease: paradigm shifts and future prospects , 2006, Nature Reviews Genetics.

[68]  N. Sonenberg,et al.  mTOR signaling: implications for cancer and anticancer therapy. , 2007, British journal of cancer.

[69]  S. Sehgal.  Sirolimus: its discovery, biological properties, and mechanism of action. , 2003, Transplantation proceedings.

[70]  D. Pierson,et al.  Growth of Streptomyces hygroscopicus in rotating-wall bioreactor under simulated microgravity inhibits rapamycin production , 2000, Applied Microbiology and Biotechnology.

[71]  A. Demain,et al.  Phosphate, ammonium, magnesium and iron nutrition ofStreptomyces hygroscopicus with respect to rapamycin biosynthesis , 1995, Journal of Industrial Microbiology.

[72]  R. Figlin,et al.  Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma , 2009, Cancer.

[73]  Suimin Qiu,et al.  Targeted Inhibition of Mammalian Target of Rapamycin Signaling Inhibits Tumorigenesis of Colorectal Cancer , 2009, Clinical Cancer Research.

[74]  Marco Pahor,et al.  Rapamycin fed late in life extends lifespan in genetically heterogeneous mice , 2009, Nature.

[75]  Zhinan Xu,et al.  A High-Throughput Method for Screening of Rapamycin-Producing Strains of Streptomyces hygroscopicus by Cultivation in 96-Well Microtiter Plates , 2005, Biotechnology Letters.

[76]  M. Gregory,et al.  Mutasynthesis of rapamycin analogues through the manipulation of a gene governing starter unit biosynthesis. , 2005, Angewandte Chemie.